Circulating Tumor Cells (CTCs) shed from primary tumor provide a window into cancer status and progression from a simple blood draw.
Serial monitoring of CTC numbers and biomarker expression levels provides critical insight into cancer drug efficacy and pharmacodynamics.
CTCs are ultra-rare cells, often present in single digit numbers in a tube of blood. This places extreme demands on any platform required to deliver accurate and reproducible CTC detection and phenotyping results.
“Using their liquid biopsy technology, RareCyte was able to develop a custom assay. Throughput the process, the RareCyte team was collaborative and insightful, showing true dedication to the project, resulting in the development of a fully validated assay.”
Erica Tobin
Associate Director, Oncology | KSQ Therapeutics, Inc.
RarePlex assays are rigorously validated for accurate and reproducible detection and phenotyping of CTCs spanning a wide range of biomarkers and indications:
